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Background: Surgical cytoreduction and endocrine blockade are important options for care for neu-
roendocrine liver metastases. We investigated the long-term survival of patients surgically treated for
hepatic neuroendocrine metastases.
Methods: Patients (n = 172) undergoing operations for neuroendocrine liver metastases from any
primary were identified from a prospective liver database. Recorded data and medical record review were
used to analyse the type of procedure, length of hospital stay, peri-operative morbidity, tumour recur-
rence, progression,and survival.
Results: The median age was 56.8 years (range 11.5–80.7 years). 48.3% of patients were female.
Median overall survival was 9.6 years (range 89 days to 22 years). On multivariate analysis, lung/thymic
primaries were associated with worse survival [hazard ratio (HR): 15.6, confidence interval (CI): 4.3–56.8,
P = 0.002]. Severe post-operative complications were also associated with worse long-term survival (P <
0.001). A positive resection margin status (R1) was not associated with a worse overall survival probability
(P ~ 0.8).
Discussion: Early and aggressive surgical management of hepatic metastases from neuroendocrine
tumours is associated with significant long-term survival rates. Radiofrequency ablation is a reasonable
option if a lesion is unresectable. R1 resections, unlike many other cancers, are not associated with a
worse overall survival.
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Introduction
Neuroendocrine carcinoma is thought to have such a biologically
indolent nature that initially the lesion of interest was referred to
as ‘carcinoma-like’, not frank carcinoma.1 This distinction is not
only of academic interest, but also extraordinarily important to
the individual patient. The ‘risk–benefit ratio’ of surgery is predi-
cated on the assumption that a patient’s disease can be accurately
(albeit, crudely) risk stratified. Clearly, there is a major difference
between benign tumours and invasive cancer. Historically,
patients with neuroendocrine lesions were felt to do relatively
well, but once metastatic disease is present, systemic therapy
is often the mainstay of treatment.2 Over 40 years ago, hepatic
resection for metastatic carcinoid tumours was considered an
option,3 yet the literature still suggests this is a controversial topic.4
There are multiple classifications for neuroendocrine tumours
(NETs). Often, they are organized by foregut, midgut and hindgut
NET. Likewise, NETs can be grouped by the prevalence of the
primary location. These are gastrointestinal carcinoids (also called
midgut neuroendocrine tumours), pancreatic islet cell tumours
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(also known as pancreatic neuroendocrine tumours, or PNETs)
and neuroendocrine tumours arising in other sites (thoracic,
thyroid, other ectodermic tissues). Most share the characteristic
of longer survival than adenocarcinomas originating from the
same organs. A recent retrospective analysis of patients with
PNETs from the Surveillance, Epidemiology and End Results
(SEER) database demonstrated a median survival of 9.5 years after
primary pancreatic resection compared with 2.9 years when resec-
tion was declined by the patient.5 Likewise, another report dem-
onstrated median disease-free survival ranges from 4.8 to 9.0 years
after resection of primary gastrointestinal carcinoid tumours.6
Clearly, when possible, resection of NET tumours may prolong
patient survival. Intriguingly, large database studies have sug-
gested a survival benefit for resection of the primary neuroendo-
crine tumour even in the setting of stage IV disease.2,5,7
Often, metastases are the hallmark of aggressive disease. This
is clearly the case in adenocarcinoma.8 Metastatic disease is
advanced disease by definition,9 but we hypothesize that meta-
static NETs isolated to the liver can be managed in a surgical
fashion as ‘advanced regional disease.’
Methods
A consecutive series of 172 patients were identified from our
prospective hepatobilliary database who underwent their first
laparotomy for treatment of neuroendocrine or carcinoid liver
metastases. All patients were diagnosed and underwent operation
between 1978 and 2009 at The University of Texas M. D. Anderson
Cancer Center in Houston, Texas. When patients underwent mul-
tiple resections, only data from the first procedure were utilized.
All patients had pathological confirmation of neuroendocrine
disease. Pre-operative imaging included chest radiograph or
chest computed tomography when indicated, as well as abdomi-
nopelvic imaging with conventional imaging (computed tomog-
raphy or magnetic resonance imaging) in all patients. In
addition, radio-nucleotide scintigraphy (i.e., octreotide scan)
was performed as standard practice since 2004. Prior to that,
many patients presented to our institution with scintigraphy
from their primary oncologist. Patients selected for surgery had
adequate functional reserve and lesion correlation on radio-
nucleotide and conventional imaging. Patients with extra-
hepatic lesions were excluded from surgery unless all disease
could be simultaneously treated during surgery. Radiofrequency
ablation (RFA) was utilized if a lesion could not be safely and
completely resected. Likewise, small tumours were often treated
with RFA if the patient was undergoing concomitant contralat-
eral hepatectomy or trisectionectomy. Complete tumour resec-
tion or RFA with preservation of sufficient hepatic parenchyma
was the key selection criterion for surgical treatment. Patients
were considered for RFA even if they had a tumour abutting a
major hepatic vein branch or the inferior vena cava. RFA was not
performed for metastases adjacent to major biliary structures,
particularly at the hepatic duct confluence.
All patients underwent resection and/or RFA during open lap-
arotomy by a hepatobiliary surgeon. No patients were treated
percutaneously, and intra-operative ultrasound was used in all
patients. All patients who underwent RFA were treated using the
RadioTherapeutics RF 2000 or RF 3000 generator system (Boston
Scientific, Natick, MA, USA) using a standard algorithm.10,11 For
tumours > 2.5 cm in diameter, the array was repositioned for
multiple treatments to obtain complete destruction of the tumour
and at least a 1-cm zone of surrounding liver parenchyma when
possible.
The Brisbane 2000 terminology of liver anatomy and resections
was used.12 Briefly, extended right hepatectomy (resection of
Couinaud segments IV + V + VI + VII + VIII  I), extended left
hepatectomy (resection of Couinaud segments II + III + IV + V +
VIII  I), right hepatectomy (resection of Couinaud segments V
+ VI + VII + VIII  I), left hepatectomy (resection of Couinaud
segments II + III + IV  I), bisegmentectomy/sectionectomy (i.e.
partial resection of 2 or 3 adjacent Couinaud segments), or seg-
mentectomy (resection of a single Couinaud segment) were per-
formed. Resection was performed with the clamp-crush method
or high-pressure water jet at the discretion of the attending
surgeon. Vascular staplers are typically used for the hepatic veins
whereas parenchymal staplers were only rarely used.
Statistical analysis
Patient demographics, primary tumour and liver tumour factors,
operative factors, pathological findings, recurrence patterns and
survival were analysed. The Cox proportional hazard model was
used to analyse differences in risk factors for survival. Hazard
ratios (HR) and 95% confidence intervals (CI) were calculated as
appropriate. Survival was estimated using Kaplan–Meier analysis;
differences in survival were analysed using the Mantel–Cox log-
rank test. Backward elimination was used to evaluate univariate
variables in the multivariate model. Variables were kept in the
model if P < 0.05. Differences in tumour recurrence rates between
treatment groups were analysed using the Fisher’s exact and two-
sided chi-square tests. Aggregated data are presented as means;
the uncertainties are standard deviations unless otherwise noted.
Differences were considered to be statistically significant when
the P-value was <0.05.
Results
Descriptive characteristics
The median patient age for the whole group was 56.8 years (range,
12 years to 81 years of age). 60.5% presented with synchronous
primary and hepatic metastatic tumours (Table 1). 48.3% were
female. 41.8% of patients received pre-operative chemotherapy
with the majority receiving 5-florouracil and streptozocin, often
prior to being evaluated at our institution. Median follow-up was
4.2 years (range 3 months to 22.9 years). All patients had patho-
logically proven primary and metastatic NET disease except for
five patients who underwent RFA only without concurrent biopsy.
These patients had pathologically proven primary disease and
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multiple types of abdominal imaging studies consistent with
metastatic NET to the liver. Fifty-nine (34.3%) patients had
only right-sided liver lesions, including isolated caudate lobe
metastases. Twenty-seven (15.7%) patients had left-sided lesions
and 84 (48.8%) had bilateral lesions. Finally, there were two
patients (1.2%) who had NET metastases at the confluence/
bifurcation with invasion into liver sections 4 and 5. Approxi-
mately half of the patients (n = 87, 50.6%) had intermediate grade
(or higher) or moderately differentiated (or worse) metastatic
NET whereas the other half had low grade or well-differentiated
lesions (n = 85, 49.4%).
Operative characteristics
One-hundred and forty patients (81.4%) underwent a hepatic
resection of some type (Table 2). Thirteen additional patients
(7.6%) were found to have diffuse metastases not amenable to
surgical treatment at the time of operation while 18 patients
(10.5%) received RFA alone without hepatic resection (where RFA
was used as definitive therapy with curative intent). The most
common primary sites of NETs (Table 3) were the small bowel
(n = 65, 37.8%) and the pancreas (n = 55, 32.0%). The eight
patients diagnosed with metastatic hepatic NETs without known
primary sites were diagnosed based on a metastatic pattern of liver
disease with biopsy proven neuroendocrine characteristics of
those lesions.
There were no staged hepatectomies. Four patients in this
series had a diagnosis of cirrhosis. Furthermore, no patient in
this series underwent pre-operative portal vein embolization.
One hundred and seventeen patients (84.2%) had negative
margins (R0) whereas 22 patients (15.8%) had positive margins
(R1 or R2).
Of the 41 patients who underwent RFA, 18 patients (43.9%)
received no other major procedure (Table 2). The median number
of tumours treated with RFA per patient was two (range 1 to 12).
Table 1 Demographic characteristics of all patients in the study
Clinical characteristics of study population (n = 172)
Characteristic Median Range
(Min–Max)
Age at surgery (years) 56.8 11.5–80.7
Length of stay (days) 7 1–30
Characteristic Number (n) % Patients
Gender
Female 83 48.3%
Male 83 48.3%
Ethnicity
Asian 2 1.1%
Black 8 4.7%
Hispanic 15 8.7%
Other 1 0.6%
Caucasian 146 84.9%
Synchronous liver metastases
at diagnosis
No 68 39.5%
Yes 104 60.5%
Synchronous non-liver resection
No 88 51.2%
Yes 84 48.8%
‘Synchronous non-liver resection’ refers to procedures where the meta-
static and primary disease (or regional lymphadenectomy) were simulta-
neously resected except for a single revision pancreaticojejunostomy.
Table 2 Major and secondary surgical treatments were performed
simultaneously for metastatic neuroendocrine tumours to the liver
(n = 172)
Major operative interventions n %
Trisectionectomy (extended hepatectomy) 22 12.8%
Hepatectomy 49 28.5%
Bisegmentectomy/sectionectomy (partial
hepatectomy)
34 19.8%
Segmentectomy 21 12.2%
Wedge resection 14 8.1%
RFA alone 18 10.5%
Cholecystectomy without resection 1 0.6%
No hepatic intervention 13 7.5%
Secondary interventions
Wedge resection 17 9.9%
RFA 23 13.4%
Segmentectomy 17 9.9%
Secondary procedures typically managed contralateral lesions not
encompassed in the simultaneous major resection because of location or
expected final liver volume. An additional 34 patients (19.8%) also under-
went a prophylactic cholecystectomy to prevent chemical cholecystitis
from future treatments, such as transarterial embolization.
Table 3 The majority of neuroendocrine tumours metastatic to the
liver are from gastrointestinal primaries
Primary location n %
Small bowel 65 37.8%
Pancreas 55 32.0%
Appendix/cecum 8 4.7%
Colon 13 7.6%
Liver 6 3.5%
Lung/thymus 6 3.5%
Rectum 2 1.2%
Thyroid 4 2.3%
Ovary/mesentery 5 2.9%
Unknown 8 4.7%
All were biopsy-proven primaries with the exception of unknown prima-
ries where hepatic lesions were biopsied prior to treatment and the
pattern was consistent with neuroendcrine metastatic disease. Hepatic
NET lesions found subsequent to primary hepatic NET resection were
classified as metastatic hepatic NET. Pancreatic primaries include func-
tional, non-functional, islet cell and non-islet cell NET.
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Nineteen patients had three or more tumours ablated while eight
patients had five or more tumours ablated. Tumours were ablated
in all eight Couinaud segments.
There were four intra-operative surgical complications (2.3%)
while the postoperative surgical complication rate was 22.1%
(Table 4). The majority of complications were Grade I or II
according to the Dindo–Clavien classification (Table 4).13 There
were no peri-operative deaths. Eighteen patients received adjuvant
chemotherapy after liver resection.
Recurrence of hepatic metastases after
surgical treatment
Eighty patients (46.5%) had recurrence of their liver metastases
after surgical therapy and their tumours were re-resected or
ablated. With a median follow-up of 5.2 years (range 0.7 years to
22.5 years), 62.5% (50/80) were still alive. 25% (20/80) of these
recurrent patients underwent a third resection/ablation for meta-
static hepatic disease. 60% (12/20) of these patients remained alive
with a median follow-up 7.5 years (range 2.7 years to 22.5 years).
Eight patients recurred after their third treatment and underwent
a fourth resection. Of this very small population, 50% (4/8)
are alive with a median follow-up of 7.6 years (range 4.9 years to
22.5 years).
Survival analysis
The median overall survival was 9.64 years (range 89 days to
22 years). Five-year overall survival was 77.4% whereas 10-year
overall survival was 50.4%. On univariate analysis (Table 5),
increasing the metastatic interval (hazard per year), increased
length of stay (hazard per day), thoracic or rectal primary site
and liver-related post-operative complications were all signifi-
cantly associated with a decrease in overall survival probability.
Less aggressive procedures were associated with a trend towards
improved overall survival (Table 5). Despite this, the intra-hepatic
location did not yield a statistically significant association with
survival on univariate or multivariate analysis.
On multivariate analysis, most of these factors were found
to be insignificant (Table 5). Two notable exceptions include
primary lung/thymus site and increasing disease-free interval
(per year) after primary resection; both were statistically associ-
ated with increasing hazard ratios for death (Table 5). In addi-
tion, late occurrences of hepatic metastases were associated with
an increased hazard for death (HR: 1.11, 95th percentile CI: 1.04–
1.18, P = 0.003). Finally, primary lesions from the colon were
associated with an increased recurrence-free survival after
hepatic metastatic resection (HR: 0.25, 95th percentile CI: 0.07–
0.80, P = 0.02).
Table 4 Peri-operative surgical complications for the 90-day period
after surgical therapy occurred in a minority of patients
Peri-operative surgical
complications
n % Grade(s)
None 134 77.9% –
Cardiac 4 2.3% I–II
Non-infectious intra-abdominal fluid
collection
4 2.3% I
Partial portal venous thrombosis or
non-fatal hepatic insufficiency
4 2.3% II–IIIa
Gastrointestinal 4 2.3% I
Pulmonary 10 5.8% I–II
Infectious 5 2.9% I–II
Others 7 4.1% I–IVa
Death 0 0.0% –
They are listed here by organ system. Cardiac complications were
typically transient atrial fibrillation. Intra-abdominal fluid collections with
positive bacterial cultures were categorized as ‘Infectious’ with urinary
tract infections, abscess, and wound infections. Gastrointestinal compli-
cations were primarily conservatively managed ileus and dysphagia at
discharge. Pulmonary complications included effusions (all conserva-
tively managed) and pneumonia. ‘Others’ included, bladder/urinary dys-
function, transient renal insufficiency and transient thrombocytopenia.
Classification is based on the Dindo–Clavien classification.13
Table 5 These are all of the variables from Tables 1 and 2 where the
univariate P-value was significant at P  0.10
Overall survival HR (95% CI) P value
Univariate analysis
Increasing interval (per year) from
primary resection to hepatic
metastases
1.11 (1.04–1.18) 0.003
Synchronous disease at diagnosis 0.55 (0.30–1.01) 0.05
Increasing length of stay (per day) 1.06 (1.00–1.12) 0.04
Primary site
Pancreas 0.53 (0.24–1.13) 0.10
Lung/thymus 5.69 (1.86–17.43) 0.002
Rectum 4.76 (1.07–21.24) 0.04
Primary procedure
Partial hepatectomy 0.11 (0.01–0.91) 0.04
Segmentectomy 0.37 (0.12–1.15) 0.09
RFA 0.35 (0.11–1.09) 0.07
Post-operative complications
Fluid collection 3.83 (0.89–16.48) 0.07
Hepatic 9.88 (2.13–45.88) 0.004
Multivariate analysis
Increasing interval from primary
resection to hepatic metastases
1.11 (1.02–1.20) 0.01
Primary site
Lung/thymus 15.63 (4.30–56.8) 0.002
Post operative complications
Fluid collection 15.89 (3.10–81.4) 0.0009
Hepatic 22.94 (4.39–120.0) 0.0002
These univariate variables were entered into a multivariate, saturated
model utilizing backward elimination to remove the insignificant variables
(P > 0.05) in a multiple regression analysis. Interestingly, margin status
(R0 vs. R1 vs. R2) and primary procedure did not meet the criteria to be
included in the multivariate model (i.e. P > 0.05).
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On multivariate analysis, recurrence-free survival after hepatic
resection of metastases was decreased for Asian patients (HR:
29.6, 95th percentile CI: 2.45–358,
P = 0.008) and those with post-operative intra-abdominal
fluid collection (HR: 6.45, 95th percentile CI: 1.42–29.3, P = 0.02),
but improved for patients with colonic primaries (HR: 0.22, 95th
percentile CI: 0.06–0.77, P = 0.02).
Positive margins (R1 or R2) were not associated with a signifi-
cantly worse overall (P ~ 0.40) or recurrence-free survival
(P ~ 0.80) probability on univariate or multivariate analysis. In
addition, no statistically significant differences based on histology
or site of origin of the primary NET were identified regarding
survival. However, having an unknown primary site led to an
improved overall survival (P < 0.001, Fig. 1) while a thoracic
primary was associated with a significantly worse survival.
Although there was decreased overall survival 8 years after a peri-
operative complication (Fig. 2), this did not reach statistical sig-
nificance (P ~ 0.10).
Of the 18 patients who received chemotherapy (non-
somatostatin analogue) after surgical treatment of hepatic
metastases, 61.1% (11/18) remained alive with a median follow-up
of 4.6 years (range 1.0–9.2 years).
Discussion
We report on the long-term survival rate of a large consecutive
series of patients with isolated neuroendocrine hepatic metastases
managed with surgery. Most importantly, there is significant long-
term survival after resection of these patients categorized with
Stage IV disease. It is the unique patient who has this ‘limited
metastatic disease,’ but these patients clearly have the potential to
benefit from an aggressive surgical approach. This patient popu-
lation represents approximately 24.5% of all stage IV NET seen at
our institution during this time frame. Furthermore, even in the
presence of a peri-operative complication (Table 4), there is no
difference in survival until over 8 years after treatment (Fig. 2),
and even then, it remains statistically insignificant (P = 0.10).
As microscopic margin status was not associated with survival,
patients benefit from an approach to remove as much NET as
possible, even if it is not an R0 resection.
Interestingly, on univariate analysis (Table 5), partial hepatec-
tomy, segmentectomy and RFA alone were associated with a trend
towards decreased hazards (i.e. increased overall survival prob-
ability). Although this was not significant on multivariate analysis,
these patients have good long-term survival rates even after
multiple resections or surgical RFA (clearly, a highly selected
Figure 1 Patients with surgically treated isolated hepatic metastatic
neuroendocrine tumours (NET) have very good long-term overall
survival. In addition, the few patients with unknown primaries did
extremely well after surgery. However, primary lesions in the thorax
(lung and thymus) did strikingly poorly after resection. These small
numbers do not permit accurate generalizations as to the cause
of this phenomenon. As deaths are from any cause in the overall
survival analysis, it is possible that the primary resection (i.e. lung
resection) contributed to long-term morbidity and mortality
Figure 2 Although peri-operative complications seem to be
associated with decreased long-term overall survival, this did not
reach statistical significance. Furthermore, there is no discernable
difference for the first 8 years after surgical treatment
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population). In addition, negative margins (R0) did not yield a
statistically significant improvement in survival probability. This
suggests that better survival is not associated with more aggressive
resection, and NET liver metastatic patients do well with anatomic
or non-anatomic resection that address their particular metastatic
disease. Specifically, as is seen in liver surgery in general, patients
with higher volumes of healthier liver parenchyma have improved
outcomes. This is consistent with the relatively indolent nature of
NET. They are, as has been described, carcinoma like, but clearly
not of the same aggressive nature. A larger patient population and
longer follow-up may eventually yield an association with degree
of resection (or location of metastases, number of segments
involved, etc.), but herein, none of this was significant in the
multivariate analysis. The only two post-operative complications
found to be associated with a decreased overall survival rate were
intra-abdominal fluid collection and liver-related complications
(insufficiency or portal venous thrombosis). It is important to not
only classify the amount of future liver remnant, but also evaluate
the effect of any previous treatments (i.e. systemic chemotherapy,
chemoembolization, etc.) on the health of the liver and evaluate
any other liver disease, particularly cirrhosis. As there is no evi-
dence that chemotherapy is of major benefit, we do not recom-
mend its use until surgical management is excluded for fear of
long-term hepatotoxicity associated with surgical treatment after
neoadjuvant chemotherapy.14 However, even after resection, there
is no major evidence that systemic chemotherapy is beneficial
suggesting a very real higher risk than potential benefit ratio.
Patients should receive systemic chemotherapy only as part of a
clinical trial.
We believe the use of a core liver biopsy before proceeding with
liver resection is reasonable in the uncommon situation where the
health of the future liver remnant is questioned. This may even be
performed as a frozen-section at the beginning of a procedure if
there is clinical evidence of unexpected liver dysfunction before
proceeding to resection.
Non-infectious post-operative intra-abdominal fluid collec-
tions were found to carry a high hazard ratio (15.9, 95% confi-
dence interval: 3.1–81.4) for death. This was surprising, and may
relate to overall liver health in the post-operative period. We
hypothesize that a globally injured liver may have increased
sinusoidal pressure (and hence increased intra-abdominal fluid)
that portends long-term liver dysfunction that either directly
or indirectly leads to a premature death. Patients with hepatic
NET metastases are not the same as patients with classic colorectal
hepatic metastases, so it is difficult to make direct comparisons or
assertions.
Late recurrences are also associated with an increased hazard
for death. Even though this disease is indolent in nature, having
late hepatic metastases is more hazardous than an early or syn-
chronous occurrence. Long-term surveillance for recurrence is
warranted. Although the most effective modality is unknown,
magnetic resonance imaging is attractive as the radiation is non-
ionizing. Until this is proven, however, local customs should
dictate the follow-up imaging modality of choice. Our practice is
to continue surveillance with CT or MR imaging on a yearly basis
for the life of the patient.
We have not described interventional vascular therapies for
liver lesions, such as hepatic artery embolization; however, others
have reported moderate success with this treatment, including
symptom palliation.2,15,16 When compared to formal resection,
embolized patients do not survive as long, suggesting that this is
an inferior procedure.2 However, patient selection is probably
related to this finding; it is difficult to declare unequivocally that
embolization therapy is inferior. Clearly from our data, we recom-
mend surgical therapy for properly selected, medically fit patients.
Others have suggested that embolization in addition to resection
is beneficial, but this has not been conclusively demonstrated.4
Finally, there does not seem to be a clear benefit of chemoembo-
lization over bland hepatic artery embolization.16 Although we
did not explicitly investigate the benefit of multidisciplinary
care teams, we are in agreement with previous studies that have
demonstrated the benefit from their use.17
Nearly all of our patients received a somatostatin analogue at
some point in their therapy, so it is difficult to extrapolate the
benefit of this therapy in this patient population. However, as part
of multimodality management of unresectable and widely meta-
static NETs, it is extremely valuable and is associated with
improved survival.2 We are not opposed to its use provided resec-
tion is not delayed. The PROMID study group demonstrated a
near doubling in time to progression with octreotide compared
with placebo in patients with unresectable NET.18 Although
unproven, it may be possible to utilize octreotide to ‘control’ the
tumour and reduce symptoms from excess hormone release while
formal workup for other metastatic disease is undertaken. There-
fore, we recommend surgical management as soon as extra-
hepatic metastatic disease is excluded in an otherwise healthy
patient.
This study demonstrates the appropriateness of early, aggres-
sive therapy to remove or destroy focal hepatic metastases in
otherwise reasonably healthy NET patients without evidence of
extrahepatic disease. In this series, there were no peri-operative
deaths after surgery for hepatic metastases. Patients who are at a
slightly higher risk for complications may benefit from the
surgery despite that higher risk. In a large volume centre,
primary tumour and metastatic resections can be safely per-
formed at the same time. RFA is a viable option for partially
resectable multicentric disease where the number or location of
metastases prevents complete resection. The presence of pre-
existing conditions may also prevent a safe resection, but permit
an ablation of lesions. Finally, the use of adjuvant chemotherapy
is unproven, but it is even more unclear as R1 margin positive
patients do relatively well after resection.
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